Literature DB >> 8163692

Distribution of plasminogen activator inhibitor in normal liver, cirrhotic liver, and liver with metastases.

P Fitch1, B Bennett, N A Booth, A Croll, S W Ewen.   

Abstract

AIMS: To examine the distribution of PAI-1 antigen in normal and cirrhotic liver and liver with metastases.
METHODS: Sections of normal and cirrhotic liver and liver with metastases were stained using the alkaline phosphatase antialkaline phosphatase (APAAP) technique and monoclonal antibody specific for plasminogen activator inhibitor (PAI-1).
RESULTS: PAI-1 antigen was identified as discrete granules in the cytoplasm of hepatocytes in normal liver, particularly around portal tracts and central veins of the liver lobule. In cirrhotic liver a striking reduction of PAI-1 antigen was noted. In liver with metastases increased amounts of PAI-1 antigen were concentrated in hepatocytes around the margins of malignant deposits.
CONCLUSIONS: Cirrhotic liver contains considerably less PAI-1 antigen than does normal liver, despite raised plasma concentrations of PAI-1. This may reflect release of hepatic PAI-1 into the circulation or decreased clearance of PAI-1 from the plasma. Secondary malignant deposits in the liver seem to stimulate production of PAI-1 in adjacent hepatocytes. This may influence the invasive process and may contribute to the thrombotic tendency associated with malignancy.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8163692      PMCID: PMC501898          DOI: 10.1136/jcp.47.3.218

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  20 in total

1.  Antifibrinolytic activity in primary carcinoma of the liver.

Authors:  H C KWAAN; R LO; A J MCFADZEAN
Journal:  Clin Sci       Date:  1959-05       Impact factor: 6.124

2.  Clearance of tissue plasminogen activator by mannose and galactose receptors in the liver.

Authors:  B Smedsrød; M Einarsson
Journal:  Thromb Haemost       Date:  1990-02-19       Impact factor: 5.249

3.  Elimination of native and carbohydrate-modified tissue plasminogen activator in rabbits.

Authors:  M Einarsson; L Hggroth; C Mattsson
Journal:  Thromb Haemost       Date:  1989-12-29       Impact factor: 5.249

4.  Complexing of tissue plasminogen activator with PAI-1, alpha 2-macroglobulin, and C1-inhibitor: studies in patients with defibrination and a fibrinolytic state after electroshock or complicated labor.

Authors:  B Bennett; A Croll; K Ferguson; N A Booth
Journal:  Blood       Date:  1990-02-01       Impact factor: 22.113

5.  Inhibition of plasminogen activators by conditioned medium of human hepatocytes and hepatoma cell line Hep G2.

Authors:  E D Sprengers; H M Princen; T Kooistra; V W van Hinsbergh
Journal:  J Lab Clin Med       Date:  1985-06

Review 6.  Hemostasis in malignancy.

Authors:  S Nand; H Messmore
Journal:  Am J Hematol       Date:  1990-09       Impact factor: 10.047

7.  Tissue plasminogen activator is endocytosed by mannose and galactose receptors of rat liver cells.

Authors:  B Smedsrød; M Einarsson; H Pertoft
Journal:  Thromb Haemost       Date:  1988-06-16       Impact factor: 5.249

8.  Regulation of the expression of type 1 plasminogen activator inhibitor in Hep G2 cells by epidermal growth factor.

Authors:  C L Lucore; S Fujii; T C Wun; B E Sobel; J J Billadello
Journal:  J Biol Chem       Date:  1988-11-05       Impact factor: 5.157

9.  Plasminogen activators and plasminogen activator inhibitors in liver deficiencies caused by chronic alcoholism or infectious hepatitis.

Authors:  C Tran-Thang; J Fasel-Felley; G Pralong; J R Hofstetter; F Bachmann; E K Kruithof
Journal:  Thromb Haemost       Date:  1989-09-29       Impact factor: 5.249

10.  Potential attenuation of fibrinolysis by growth factors released from platelets and their pharmacologic implications.

Authors:  S Fujii; C L Lucore; W E Hopkins; J J Billadello; B E Sobel
Journal:  Am J Cardiol       Date:  1989-06-15       Impact factor: 2.778

View more
  3 in total

1.  Hyperfibrinolysis in hepatosplenic schistosomiasis.

Authors:  N E el-Bassiouni; A E el Bassiouny; H R el-Khayat; M M Akl; S A Omran
Journal:  J Clin Pathol       Date:  1996-12       Impact factor: 3.411

2.  Paediatric cholestatic liver disease: Diagnosis, assessment of disease progression and mechanisms of fibrogenesis.

Authors:  Tamara N Pereira; Meagan J Walsh; Peter J Lewindon; Grant A Ramm
Journal:  World J Gastrointest Pathophysiol       Date:  2010-06-15

Review 3.  Aetiopathogenesis of liver changes in the course of cystic fibrosis, considering disturbances of the bile acid profile as well as genetic and immunological factors.

Authors:  Sabina Więcek; Halina Woś; Urszula Grzybowska-Chlebowczyk
Journal:  Prz Gastroenterol       Date:  2013-10-28
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.